
|Videos|June 6, 2017
Neratinib Shrank Brain Mets in Half of HER2+ Breast Cancer Patients
Author(s)Rachel A. Freedman, MD, MPH
This video examines results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients.
Advertisement
In this video, Rachel A. Freedman, MD, MPH, of the Dana-Farber Cancer Institute, discusses results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients.
Freedman presented the results of the study (
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Sunvozertinib Improves PFS vs Chemotherapy in EGFR+ NSCLC
2
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
3
The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes
4
Considering Venlafaxine as Distress Treatment in Breast Cancer
5



















































